Skip to main
SMTI
SMTI logo

SMTI Stock Forecast & Price Target

SMTI Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sanara MedTech has demonstrated significant growth in its surgical and chronic wound care product lines, with surgical soft tissue repair products increasing 24% year-over-year to $23.4 million, driven predominantly by the demand for CellerateRX Surgical. The company has implemented an effective strategy to expand its distribution network and healthcare facility partnerships, which could further enhance its revenue growth trajectory. Additionally, the anticipation of profitability in the third quarter of 2025 underscores a positive shift in financial stability and operational efficiency for Sanara MedTech.

Bears say

Sanara MedTech reported net revenue of $26.3 million, marking a 21.5% year-over-year growth that fell slightly short of projections. The company faces significant risks including lower-than-anticipated revenue growth, challenges in securing new customers, difficulties in launching new products or services, and the potential for dilution. Additionally, the reduction of the enterprise value to revenue multiple from 4.3x to 3.0x indicates a declining market sentiment, particularly in light of telehealth no longer being part of the business strategy.

SMTI has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sanara MedTech Inc. (SMTI) Forecast

Analysts have given SMTI a Buy based on their latest research and market trends.

According to 2 analysts, SMTI has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sanara MedTech Inc. (SMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.